Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prestige Consumer Healthcare (PBH) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Prestige Consumer Healthcare (PBH) over the last 17 years, with Q4 2025 value amounting to $44000.0.

  • Prestige Consumer Healthcare's Gains from Investment Securities changed N/A to $44000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $4.3 million, marking a year-over-year decrease of 2695.47%. This contributed to the annual value of $5.8 million for FY2025, which is 588.24% up from last year.
  • Per Prestige Consumer Healthcare's latest filing, its Gains from Investment Securities stood at $44000.0 for Q4 2025.
  • Prestige Consumer Healthcare's 5-year Gains from Investment Securities high stood at $6.6 million for Q1 2021, and its period low was $16000.0 during Q4 2022.
  • Moreover, its 5-year median value for Gains from Investment Securities was $3.5 million (2021), whereas its average is $3.1 million.
  • Over the last 5 years, Prestige Consumer Healthcare's Gains from Investment Securities had its largest YoY gain of 42258.06% in 2025, and its largest YoY loss of 3011.55% in 2025.
  • Prestige Consumer Healthcare's Gains from Investment Securities (Quarter) stood at $2.9 million in 2021, then tumbled by 99.45% to $16000.0 in 2022, then soared by 34325.0% to $5.5 million in 2023, then tumbled by 99.44% to $31000.0 in 2024, then skyrocketed by 41.94% to $44000.0 in 2025.
  • Its Gains from Investment Securities stands at $44000.0 for Q4 2025, versus $162000.0 for Q3 2025 and $4.1 million for Q2 2025.